Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus

Bone Marrow Transplant. 2024 Jun;59(6):904-906. doi: 10.1038/s41409-024-02263-w. Epub 2024 Mar 11.

Authors

Mohammad Alhomoud¹, Michael Scordo^{1

2}, Miguel-Angel Perales^{3

4}

Affiliations

¹ Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Weill Cornell Medical College, New York, NY, USA.
³ Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. peralesm@mskcc.org.
⁴ Weill Cornell Medical College, New York, NY, USA. peralesm@mskcc.org.

PMID: 38467748
DOI: 10.1038/s41409-024-02263-w

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allografts
Antibodies, Monoclonal, Humanized / therapeutic use
Female
Hematopoietic Stem Cell Transplantation / adverse effects
Hematopoietic Stem Cell Transplantation / methods
Humans
Male
Middle Aged
Sirolimus* / therapeutic use
Thrombotic Microangiopathies* / etiology
Transplantation, Homologous / methods

Substances

Sirolimus
Antibodies, Monoclonal, Humanized